The human body has the capacity to produce an array of specialised T cells, which provide unique responses to a diverse range of tumour cells and pathogens.
In its latest white paper, biopharmaceutical expert, Sartorius, explains why the modulation of T cells is an exciting prospect for the development of novel therapies for immuno-oncology –autoimmune applications, adoptive cell therapy and vaccine development.
The company’s aim is to empower scientists to simplify and accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine.
The white paper provides an overview of the importance of understanding T Cell biology, for building better therapeutics. The use of advanced flow cytometry to study the processes controlling T cell activation, killing and exhaustion, in cases of Patient to Patient Variability, BiTE antibody evaluation and CAR-T cell characterisation, is discussed.
You will be able to read how the iQue 3 advanced flow cytometry platform, provides a rapid, high throughput solution to the study or monitoring of T cell function and phenotype, plus helps to identify early biomarkers or perform serological characterisations.
To download the white paper click here
